Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A meta-analysis of aggregate data
Does hormone therapy after radiotherapy offer an advantage over radiotherapy alone for those diagnosed with localised prostate cancer?
What is this study about?
For men with prostate cancer that hasn’t spread to other parts of their bodies (localised), surgery (called a ‘radical prostatectomy’) is the standard of care. Radiotherapy or hormone therapy is typically only used as treatment for those men whose cancer has spread. A few randomised trials have attempted to assess whether giving hormone therapy alongside radiotherapy before the cancer has spread stops the spread and helps men to live longer.
A systematic review and meta-analysis is ongoing, based on trial results. The DADSPORT meta-analysis includes both published and unpublished results from four randomised trials, including RADICALS-HD, with a total of 5,484 participants across all trials.
Preliminary results were presented at the European Society of Medical Oncology (ESMO) meeting in 2022. Further results have been collected and final results are expect early 2024.
Type of study
Who is funding the study?
This study is funded by the Medical Research Council.
When is it taking place?
The study is ongoing and the included trials recruited men between 2006 and 2015.
Where is it taking place?
This study is being done at the MRC Clinical Trials Unit at UCL, but brings together the results of trials from all over the world.
Who is included?
This study brought together four trials (comprising 5,484 patients in total) that studied the addition of hormone therapy to radiotherapy versus radiotherapy alone, in those localised prostate cancer.